Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 15/20 | 0.71 |
| ▸ | MAOB | P27338 | 5/20 | 0.71 |
| ▸ | AOC2 | O75106 | 5/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | DAO | P14920 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22477328 | 0.84 | AOC3 (0.61) | AOC3MAOBAOC2 | |
| SCHEMBL16767507 | 0.83 | AOC3 (1.00) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL16766991 | 0.83 | AOC3 (1.00) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL16766988 | 0.83 | AOC3 (1.00) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL21865250 | 0.83 | AOC3 (0.63) | AOC3MAOBAOC2MAOADAO | |
| Hydrochloric Acid SCHEMBL16766775 | 0.82 | AOC3 (1.00) | AOC3MAOBAOC2MAOADAO | |
| Hydrochloric Acid SCHEMBL15528246 | 0.82 | AOC3 (1.00) | AOC3MAOBAOC2MAOADAO | |
| Hydrochloric Acid SCHEMBL15528250 | 0.82 | AOC3 (1.00) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL30527072 | 0.78 | AOC2 (0.49) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL22462047 | 0.78 | AOC2 (0.49) | AOC3MAOBAOC2MAOADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3715341-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101086-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | VAPB, VAPA, ADRA1D | AOC3 79/4885MAOB 1567/4885AOC2 102/4885 |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | VAPB, VAPA, ADRA1D | AOC3 79/4885MAOB 1567/4885AOC2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.